Skip to content

Treatment of Hypertension

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000484
Enrollment
Unknown
Registered
1999-10-28
Start date
1966-04-30
Completion date
1979-01-31
Last updated
2013-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Heart Diseases, Hypertension, Vascular Diseases

Brief summary

To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.

Detailed description

BACKGROUND: This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo. The study completion date listed in this record was inferred from last publication listed in the Citations section of this study record.

Interventions

DRUGRauwolfia alkaloids

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026